Cargando…

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Aim: As weight gain and hypoglycaemia associated with glimepiride therapy can negatively impact weight perceptions, psychological well-being and overall quality of life in type 2 diabetes, we investigated whether liraglutide treatment could improve these factors. Methods: Seven hundred and thirty-tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bode, B W, Testa, M A, Magwire, M, Hale, P M, Hammer, M, Blonde, L, Garber, A
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2010
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901519/ https://www.ncbi.nlm.nih.gov/pubmed/20590735 http://dx.doi.org/10.1111/j.1463-1326.2010.01196.x

Ejemplares similares

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
por: Garber, A, et al.
Publicado: (2011)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues—Liraglutide and Semaglutide
por: Basalay, Maryna V., et al.
Publicado: (2019)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling
por: Chang, Ching-Chi, et al.
Publicado: (2018)

Monotherapy with liraglutide – Points to be focussed
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019)

Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes
por: Aung, Myo Myo, et al.
Publicado: (2019)

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide
por: Barnett, A H
Publicado: (2012)

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model
por: Parthsarathy, Vadivel, et al.
Publicado: (2013)

Counselling Patients for GLP-1 Analogue Therapy: Comparing GLP-1 Analogue with Insulin Counselling
por: Kalra, Sanjay, et al.
Publicado: (2012)

The effects of a GLP-1 analogue liraglutide on reward value and the learned inhibition of appetitive behavior in male and female rats
por: Jones, Sabrina, et al.
Publicado: (2018)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

The Risk of Overall Mortality in Patients With Type 2 Diabetes Receiving Glipizide, Glyburide, or Glimepiride Monotherapy: A retrospective analysis
por: Pantalone, Kevin M., et al.
Publicado: (2010)

Comparison of the Efficacy of Glimepiride, Metformin, and Rosiglitazone Monotherapy in Korean Drug-Naïve Type 2 Diabetic Patients: The Practical Evidence of Antidiabetic Monotherapy Study
por: Yoon, Kun Ho, et al.
Publicado: (2011)

Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
por: Femminella, Grazia Daniela, et al.
Publicado: (2019)

GLP-1 Analogue Liraglutide Enhances SP-A Expression in LPS-Induced Acute Lung Injury through the TTF-1 Signaling Pathway
por: Zhu, Tao, et al.
Publicado: (2018)

Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)
por: Femminella, Grazia Daniela, et al.
Publicado: (2020)

SAT-635 Results of a Preclinical Pilot Study Evaluating 24-Hour Subcutaneous Infusion of the GLP-1 Analogue Liraglutide Delivered via the H-Patch Wearable Device
por: Barnes, Jessica W, et al.
Publicado: (2020)

A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures
por: Patel, Charmi A., et al.
Publicado: (2016)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Accidental exposure to glimepiride from adulterated medication resulting in severe hypoglycaemia
por: Hayes, Annabelle G, et al.
Publicado: (2022)

Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials
por: Zhu, Hongmei, et al.
Publicado: (2013)

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
por: Zinman, Bernard, et al.
Publicado: (2009)

Short-term monotherapy with Liraglutide for weight management: A case study
por: Almarshad, Feras
Publicado: (2019)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?
por: Ahrén, Bo, et al.
Publicado: (2014)

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus
por: Cho, Eun-Hee, et al.
Publicado: (2020)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015)

Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
por: Williams, David M., et al.
Publicado: (2020)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial
por: Kondo, Yaeko, et al.
Publicado: (2016)

Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study
por: Inoue, Kana, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ufgfiut4vvbhj5flupo5voeubh